ANTICOAGULANT PROTEIN

Novel EPI analogues are provided wherein one or more of the amino acid residues of native EPI have been deleted. A preferred group of the novel EPI analogues have no or a low heparin binding capacity. The novel EPI analogues can be used for the treatment of patients having coagulation disorders or c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	RASMUSSEN, JESPER, SKOU, NORDFANG, OLE, JUUL
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Novel EPI analogues are provided wherein one or more of the amino acid residues of native EPI have been deleted. A preferred group of the novel EPI analogues have no or a low heparin binding capacity. The novel EPI analogues can be used for the treatment of patients having coagulation disorders or cancer. Nouveaux analogues d'EPI dans lesquels un ou plusieurs restes d'acide aminé d'EPI natif ont été supprimés. Le groupe préféré des nouveaux analogues d'EPI ne présente pas ou peu d'activité de liaison de l'héparine. On peut utiliser les nouveaux analogues d'EPI dans le traitement de patient atteint de troubles de la coagulation ou d'un cancer.